{"organizations": [], "uuid": "8105c14ace95197fbe723b02b78a8a04b18602cc", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-vaxil-obtains-us-patent-for-signal/brief-vaxil-obtains-u-s-patent-for-signal-peptide-antibody-platform-idUSFWN1QJ0U9", "country": "US", "domain_rank": 408, "title": "BRIEF-Vaxil‍ Obtains U.S. Patent For Signal Peptide Antibody Platform", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-03-01T15:45:00.000+02:00", "replies_count": 0, "uuid": "8105c14ace95197fbe723b02b78a8a04b18602cc"}, "author": "", "url": "https://www.reuters.com/article/brief-vaxil-obtains-us-patent-for-signal/brief-vaxil-obtains-u-s-patent-for-signal-peptide-antibody-platform-idUSFWN1QJ0U9", "ord_in_thread": 0, "title": "BRIEF-Vaxil‍ Obtains U.S. Patent For Signal Peptide Antibody Platform", "locations": [], "entities": {"persons": [{"name": "saeid babaei", "sentiment": "none"}, {"name": "isaac maresky", "sentiment": "none"}], "locations": [{"name": "u.s.", "sentiment": "none"}], "organizations": [{"name": "brief-vaxil‍ obtains u.s. patent for signal peptide antibody platform", "sentiment": "neutral"}, {"name": "brief-vaxil‍ obtains u.s. patent for signal peptide antibody", "sentiment": "neutral"}, {"name": "reuters", "sentiment": "none"}, {"name": "vaxil bio ltd", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "March 1, 2018 / 1:47 PM / in 12 minutes BRIEF-Vaxil‍ Obtains U.S. Patent For Signal Peptide Antibody Platform Reuters Staff 1 Min Read March 1 (Reuters) - Vaxil Bio Ltd: * VAXIL BIO LTD - ‍ OBTAINED A U.S. PATENT FOR ITS SIGNAL PEPTIDE ANTIBODY PLATFORM KNOWN AS SPMAB​ * VAXIL BIO LTD - ‍ SAEID BABAEI HAS RESIGNED FROM HIS ROLE AS CHAIRMAN OF BOARD​ * VAXIL BIO LTD - ‍ISAAC MARESKY HAS ACCEPTED ROLE OF CHAIRMAN FOR TIME BEING​ Source text for Eikon:  ", "external_links": [], "published": "2018-03-01T15:45:00.000+02:00", "crawled": "2018-03-01T16:01:18.000+02:00", "highlightTitle": ""}